Main Article Content
Implantable drug delivery system is a modified release dosage form. To improve quality of life of patients, implants are alternative drug delivery systems. The crucial advantages of these drug delivery systems over conventional delivery systems (oral and parenteral dosage form) are direct delivery to target with a constant rate, low dose required for treatment, avoidance probable systemic side effects, probable to control of drug release, high efficacy of treatment and dose termination is possible. However, the limitations of these drug delivery systems are invasive, limit to potent drug, uncomfortable feeling and biocompatibility issues. Therefore, implantable drug delivery systems are still need to be developed to optimize the technology of several drug products and to enhance efficacy, safety and stability. The available types and technologies of implantable dosage form are the main focus of this review.
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
Craig PH, Williams JA, Davis KW, Magoun AD, Levy AJ, Bogdansky S, et al., A biologic comparison of polyglactin 910 and polyglycolic acid synthetic absorbable sutures. Surg Gynecol Obstet 1975; 141(1): 1-10.
Cutright DE, Beasley JD, 3rd, Perez B, Histologic comparison of polylactic and polyglycolic acid sutures. Oral Surg Oral Med Oral Pathol 1971; 32(1): 165-173.
Dadey EJ, The Atrigel® Drug Delivery System, in Modified-Release Drug Delivery Technology, Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, ed. 2008, Informa Healthcare USA Inc.: New York. p. 183-189.
Duma TJ, Akers MJ, Parenteral Drug Administration: Routes, Precautions, Problems, and Complications, in Pharmaceutical Dosage Form: Parenteral Medications, Avis KE, Lachman L, Lieberman HA, ed. 1984, New York: Marcle Dekker, Inc. p. 13-45.
DURECT Corporation. ALZET® Osmotic Pumps: small, infusion pumps for continuous dosing of unrestrained laboratory animals. 2015b [cited Mar 25, 2015]; Available from: http://www.alzet.com/.
DURECT Corporation. The Duros Technology. 2015a [cited Mar 25, 2015]; Available from: http://www.durect.com/wt/durect/page_name/duros.
Elstad NL, Fowers KD, OncoGel (ReGel/paclitaxel) — Clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev 2009; 61(10): 785-794.
Folkman J, Long DM, Jr., Rosenbaum R, Silicone rubber: a new diffusion property useful for general anesthesia. Science 1966; 154(3745): 148-149.
Folkman J, Long DM, The use of silicone rubber as a carrier for prolonged drug therapy. J Surg Res 1964; 4: 139-142.
Fung LK, Saltzman WM, Polymeric implants for cancer chemotherapy. Adv Drug Deliv Rev 1997; 26(2–3): 209-230.
Fung LK, Theoretical and experimental pharmacokinetics of polymer delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a rat brain model, in Chemical Engineering, ed. 1996, The Johns Hopkins University: Baltimore.
Gombotz WR, Pettit DK, Biodegradable Polymers for Protein and Peptide Drug Delivery. Bioconjugate Chem 1995; 6(4): 332-351.
Gorbakov V, editor Interim results from a Phase 2 study of Omega Interferon in HCV. In: Proceeding of the 56th Annual meeting of the American Association for the Study of Liver Diseases; 2005; San Francisco, CA.
Intarcia Therapeutics. Phase 1b study of Omega DUROS® in patients with chronic hepatitis C who relapsed after prior treatment. 2015 March 12, 2015 [cited March 17, 2015]; Available from: https://clinicaltrials.gov/ct2/show/NCT00519792.
Lane ME, Okumu FW, Balausubramanian P, Injections and Implants, in Modified-Release Drug Delivery Technology, Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, ed. 2008, Informa Healthcare USA Inc.: New York. p. 123-131.
Mark L, Luteinizing hormone-release hormone agonists in the treatment of men with prostate cancer: timing, alyernatives, and the 1-year implant. Urology 2003; 62(6 (Suppl. 1)): 36-42.
Okada H, Toguchi H, Biodegradable Microspheres in Drug Delivery. Crit Rev Ther Drug Carrier Syst 1995; 12(1): 1-99.
Prasertsilapa W. Targeted Therapy. 2015 [cited; Available from: http://www.gpo.or.th/rdi1/html/targeted_ therapy.html.
Rathi RC, Fowers KD, ReGel Depot Technology, in Modified-Release Drug Delivery Technology, Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, ed. 2008, Informa Healthcare USA Inc.: New York. p. 171-181.
Rohloff C, Alessi T, Yang B, Dahms J, Carr J, Lautenbach S, DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months. J Diabetes Sci Technol 2008; 2(3): 461-467.
Sivin I, Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Saf 2003; 25(5): 303-335.
Storm P, Clatterbuck R, Liu Y, Johnson R, Gillis E, Guarnieri M, et al., A surgical technique for safely placing a drug delivery catheter into the pons of primates: preliminary results of carboplatin infusion. Neurosurgery 2003; 52(5): 1169-1176.
Strege R, Liu Y, Kiely A, Johnson R, Gillis E, Storm P, et al., Toxicity and cerebrospinal fluid levels of carboplatin chronically infused into the brainstem of a primate. J Neurooncol 2004; 67(3): 327-334.
Weingaart J, Rhines L, Brem H, Intratumoral chemotherapy, in Neuro-Oncology: The essentials, Bernstein M, Berger M, ed. 2000, Thieme Medical Publishers, Inc.: New York. p. 240-248.
Wright J, Johnson R, Yum S, DUROS® osmotic pharmaceutical systems for parenteral and site-directed therapy. Drug Deliv Technol 2003a; 3(1): 3-11.
Wright JC, Bannister R, Chen G, Lucas C, Alzamer Depot Bioerodible Polymer Technology, in Modified-Release Drug DeliveryTechnology, Rathbine MJ, ed. 2003, Marcel Dekker, Inc: New York. p. 639-646.
Wright JC, Verity AN, Okumu FW, The SABERTM Delivery System for Parenteral Administration, in Modified-Release Drug Delivery Technology, Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, ed. 2008, Informa Healthcare USA Inc.: New York. p. 151-158.
Wu MP, Tamada JA, Brem H, Langer R, In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy. J Biomed Mater Res 1994; 28(3): 387-395.